Find clinical trials for Leukemia in Cincinnati, OH
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Leukemia trials near Cincinnati, OH, USA:
Phase 2 dose (RP2D) of SNDX-5613 in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 47 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Cincinnati, Ohio, United States and 110 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Cincinnati, Ohio, United States and 43 other locations
The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs. F...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 33 other locations
The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared wi...
Phase 3
Cincinnati, Ohio, United States and 240 other locations
of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...
Phase 3
Cincinnati, Ohio, United States and 134 other locations
chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or...
Phase 1
Cincinnati, Ohio, United States and 10 other locations
of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed ...
Phase 1, Phase 2
Cincinnati, Ohio, United States and 34 other locations
This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in patients with CML-CP without T315I mutation who have had a...
Phase 3
Cincinnati, Ohio, United States and 22 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Cincinnati, Ohio, United States and 21 other locations
Clinical trials
Research sites
Resources
Legal